Shanghai Tongren Pharmaceutical Co., Ltd. (上海同仁药业股份有限公司)

概览

关联

21

项与上海同仁药业股份有限公司相关的临床试验

Shanghai Three-Year Action Plan for Strengthening the Construction of Public Health System (2023-2025) Key Discipline (GWV1-11.1-29 - Epidemiology of Chronic Diseases - Research on health management strategies and applications in the elderly population)

开始日期2024-06-15

申办/合作机构

上海同仁药业股份有限公司

ChiCTR2400083633 / Suspended早期临床1期

Patient-derived cancer organoid cultures to predict the clinical efficacy of first-line immunotherapy plus chemotherapy in advanced gastric cancer: A prospective multicenter observational study

开始日期2024-04-30

申办/合作机构

上海同仁药业股份有限公司

ChiCTR2300074531 / Suspended早期临床1期

A prospective, single-arm, multicenter clinical study of cadonilimab combined with surufatinib in the treatment of progress advanced soft tissue sarcoma after system chemotherapy

开始日期2023-08-18

申办/合作机构

上海同仁药业股份有限公司

100 项与上海同仁药业股份有限公司相关的临床结果

登录后查看更多信息

0 项与上海同仁药业股份有限公司相关的专利（医药）

登录后查看更多信息

1

项与上海同仁药业股份有限公司相关的文献（医药）

Zhongguo Yiyao Gongye Zazhi

Synthesis of diclazuril

作者: He, Linhua ; Mei, Yukui ; Peng, Zhulun

The protozoacide Diclazuril was synthesized by substituting 3,4,5-trichloronitrobenzene with 4-chlorophenylacetonitrile in the presence of NaOH, reducing with Fe/NH₄Cl, diazotizing with NaNO₂/HCl and adding with Et cyanoacetylcarbamate to obtain Et [2-[4-(4-chlorophenylcyanomethyl)-3,5-dichlorophenylhydrazo]-2-cyanoacetyl]carbamate, cyclizing intramolecularly in acetic acid in the presence of KOAc under refluxing for 2 h, and hydrolyzing and decarboxylating with 36% HCl and mercaptoacetic acid under refluxing for 8 h, etc.

100 项与上海同仁药业股份有限公司相关的药物交易

登录后查看更多信息

100 项与上海同仁药业股份有限公司相关的转化医学

登录后查看更多信息